Corporate Strategy

Our goal is to become a fully integrated biotechnology company by developing Anticalin therapeutics in diseases with high unmet medical need and eventually commercializing our products. While we will engage with partners for many of our programs we intend to retain certain development and commercial rights to specific products as our experience in drug development continues to grow. Key elements of our strategy include:

  • Advance our lead drug candidates, PRS-080 (anti-hepcidin) and PRS-060 (anti-IL4Ra) into and through clinical trials. In November 2014, we began a Phase I clinical trial with PRS-080 in healthy volunteers. Following completion of this trial, we plan to conduct biomarker-driven Phase II efficacy trials in chronic kidney disease (CKD) patients suffering from functional iron deficiency (FID) anemia. For PRS-060, our inhalable anti-IL4Ra Anticalin protein for severe asthma, we are currently exploring different collaboration options. Together with a partner, we intend to conduct further IND-enabling activities to move into clinical development as quickly as possible.
  • Develop and broaden our Immuno-Oncology franchise. Within our PRS-300-Series, we are developing bi- and multispecific Anticalin-Antibody fusion proteins against a variety of immune checkpoint and tumor targets.  Based on the promise of such immunomodulatory approaches to treat cancer and our ability to generate highly differentiated molecules with novel modes of action, we intend to make this area a core franchise of Pieris.
  • Continue to build our platform by entering into new partnerships and advancing our currently-partnered programs. We have active partnerships in a diverse range of therapeutic areas and geographies. Our partners include global pharmaceutical companies, such as Sanofi group and Daiichi Sankyo, as well as two pharmaceutical companies based in India, Zydus Cadila and Stelis Biopharma. Together with these partners, we intend to advance multiple drug candidates through preclinical and clinical studies. As we continue to improve on the Anticalin platform technology, we will continue to engage with new pharmaceutical partners that want to combine their disease and target know-how with our ability to generate highly differentiated Anticalin drug candidates.